The Patent Finder
AP

Adamas Pharmaceuticals, Inc.

First filing 2002
OverviewNotableFeesChangesFamiliesPatent listSources & methods

11 patents currently held

7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2028. from the record

Of the 7 now held by other companies, 6 name Adamas Pharma LLC as their current owner, and 1 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Jan 2028
Next term end
5
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 5 fees due Jun 5 to 24, 2027 · next Jun 5
  • 1 fee due Aug 6, 2027
    The maintenance fee for Composition and Method for Treating Neurological Disease (US 11,890,261) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 8,389,578Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
US 7,858,660Compositions and Kits for Treating Influenza
In force
 · Medium confidence
In forceMedium confidence
US 8,058,291Methods and Compositions for the Treatment of Cns-Related Conditions
In force
 · High confidence
In forceHigh confidence
US 10,213,393Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
US 10,213,394Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
US 10,500,170Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
US 10,500,171Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
US 10,500,172Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
US 10,512,617Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
US 11,833,121Composition and Method for Treating Neurological Disease
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 7 patents in force now held by others · 26 patents ended · 59 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited